Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Instagram Outage Disrupts Thousands of U.S. Users 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
NEW ORLEANS, Nov. 08, 2016 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until January 5, 2017 to file lead plaintiff applications in securities class action lawsuit against Teva Pharmaceutical Industries Limited (NYSE:TEVA), if they purchased the Company’s American Depositary Shares between February 10, 2015 and November 3, 2016, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.
What You May Do
If you purchased shares of Teva and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by January 5, 2017.
About the Lawsuit
Teva and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On November 3, 2016, Bloomberg reported that an “antitrust investigation by the Justice Department, begun about two years ago, now spans more than a dozen companies,” including Teva, “and about two dozen drugs.” The article further stated that a “grand jury probe is examining whether some executives agreed with one another to raise prices, and the first charges could emerge by the end of the year.” Additionally, according to Bloomberg, “[g]eneric drug companies are also contending with a civil price-fixing investigation by [the] Connecticut Attorney General.”
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
